Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (Diluted Average) (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $1250.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) changed 0.0% year-over-year to $1250.0, compared with a TTM value of $1250.0 through Sep 2025, changed 0.0%, and an annual FY2024 reading of $1250.0, down 100.0% over the prior year.
  • Shares Outstanding (Diluted Average) was $1250.0 for Q3 2025 at Ovid Therapeutics, down from $71.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $71.2 million in Q2 2024 and bottomed at $1250.0 in Q1 2024.
  • Average Shares Outstanding (Diluted Average) over 5 years is $51.4 million, with a median of $70.3 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 16.45% in 2021, then crashed 100.0% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $68.1 million in 2021, then rose by 3.46% to $70.4 million in 2022, then rose by 0.22% to $70.6 million in 2023, then plummeted by 100.0% to $1250.0 in 2024, then changed by 0.0% to $1250.0 in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for OVID at $1250.0 in Q3 2025, $71.1 million in Q2 2025, and $1250.0 in Q1 2025.